(Q39356901)

11 September 2017

Combination therapy for advanced resistant Hodgkin's disease (English)

2 references

11 September 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A53720

8 April 2022

author name string

J. M. Goldman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A53720

8 April 2022

A. A. Dawson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A53720

8 April 2022

language of work or name

English

0 references

publication date

1 December 1975

1 reference

11 September 2017

20 December 1975

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=53720

full work available at URL

8 April 2022

https://api.elsevier.com/content/article/PII:S0140673675920693?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(75)92069-3

https://api.elsevier.com/content/article/PII:S0140673675920693?httpAccept=text/plain

8 April 2022

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(75)92069-3

8 April 2022

1 reference

11 September 2017

2

1 reference

11 September 2017

7947

1 reference

11 September 2017

1224-1227

1 reference

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

Combination chemotherapy in generalized Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

Alkylating Activity of 1,3-Bis(2-chloroethyl)-1-nitrosourea and Related Compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

Combination chemotherapy of advanced Hodgkin's disease. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

BCNU (1,3), BIS(B-chloroethyl)-1-nitrosourea. Effects on advanced Hodgkin's disease and other neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

Treatment of Advanced Hodgkin’s Disease with [1,3 Bis (2-Chloroethyl)-1-Nitrosourea] BCNU

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

Early clinical experience with bleomycin in the United Kingdom in series of 105 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

Recent trends in the medical treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2875%2992069-3

7 January 2021

6

26

1311

Lukes

1966

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(75)92069-3

8 April 2022

7

26

1310

Rosenberg

1966

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(75)92069-3

8 April 2022

8

31

1860

Carbone

1971

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(75)92069-3

8 April 2022

Identifiers

1 reference

11 September 2017

1 reference